Article
Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer.
Cancer treatment and research communications - 1 Jan 2025
Levine Kevin M, Uy Natalie F, Gooley Ted A, Voutsinas Jenna, Tratt Micah, Eaton Keith D, Santana-Davila Rafael, Berger Alice H, Baik Christina S
Abstract excerpt
Resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor, remains a key challenge in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Although retreatment with earlier-generation EGFR tyrosine kinase inhibitors has been studied, data on osimertinib rechallenge are limited. We conducted a single institution retrospective analysis of patients with EGFR-mutated NSCLC who were...
Topics
- Humans
- Aniline Compounds
- Acrylamides
- Carcinoma, Non-Small-Cell Lung
- Male
- Lung Neoplasms
- Female
- Middle Aged
- Aged
- ErbB Receptors
- Retrospective Studies
- Mutation
- Retreatment
- Protein Kinase Inhibitors